eligibility_summary
Eligibility: CD19+ B-ALL or B-NHL refractory to >=2 lines or relapsed (incl post-HSCT), age 1-60, adequate renal/hepatic/cardiac/pulmonary function, ANC >=1000, ALC >=100, platelets >=75k, Hgb >=8, consent and contraception. Exclude: CNS involvement/disease, VOD, tumor complications, hemolysis, PID, autoimmune neuro, immunosuppression > low-dose steroids, GvHD, active infection, critical illness/ECOG>=3, severe comorbidity, recent unstable angina, other cancers, excipient allergy, pregnancy/breastfeeding, other trial.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06027957 tests autologous anti‑CD19 CAR T cells for relapsed/refractory CD19+ B‑cell NHL and ALL. Intervention: single IV infusion (1–2×10^6 cells/kg) of patient T cells genetically engineered with a chimeric antigen receptor that binds CD19 and triggers T‑cell activation (via CD3ζ/costimulation), leading to perforin/granzyme‑mediated lysis of malignant B cells and on‑target B‑cell aplasia. Preconditioning lymphodepletion: fludarabine (purine analog antimetabolite) and cyclophosphamide (alkylating, immunosuppressive) with mesna (uroprotectant) to reduce host lymphocytes and support CAR‑T expansion. Targets: CD19 on malignant/normal B cells, activation of T‑cell effector pathways and homeostatic cytokines (IL‑7/IL‑15).